An organized and functional thymus generated from FOXN1-reprogrammed fibroblasts

Nicholas Bredenkamp1,3, Svetlana Ulyanchenko1, Kathy Emma O’Neill1, Nancy Ruth Manley2, Harsh Jayesh Vaidya1 and Catherine Clare Blackburn1,4

A central goal of regenerative medicine is to generate transplantable organs from cells derived or expanded in vitro. Although numerous studies have demonstrated the production of defined cell types in vitro1, the creation of a fully intact organ has not been reported. The transcription factor forkhead box N1 (FOXN1) is critically required for development of thymic epithelial cells2,3 (TECs), a key cell type of the thymic stroma4. Here, we show that enforced Foxn1 expression is sufficient to reprogramme fibroblasts into functional TECs, an unrelated cell type across a germ-layer boundary. These FOXN1-induced TECs (iTECs) supported efficient development of both CD4+ and CD8+ T cells in vitro. On transplantation, iTECs established a complete, fully organized and functional thymus, that contained all of the TEC subtypes required to support T-cell differentiation and populated the recipient immune system with T cells. iTECs thus demonstrate that cellular reprogramming approaches can be used to generate an entire organ, and open the possibility of widespread use of thymus transplantation to boost immune function in patients.

The thymus, the primary lymphoid organ crucially required for generation of a functional T-cell repertoire5, is the first organ to degenerate during normal ageing, a process termed age-related thymic involution (thymic involution herein)6. Thymic involution is a critical factor in the impaired capacity of adult patients to recover adaptive immunity following therapeutic immune depletion7. Thus, development of improved thymus-based therapies for enhancing immune system function in patients is of broad interest. TECs are critical effectors in the intrathymic microenvironments required for T-cell development. Two distinct TEC sublineages exist, located in the cortical and medullary compartments of the thymus8. These cortical (c) and medullary (m) TECs mediate discrete aspects of T-cell development, and their segregation into distinct compartments is thought vital for accurate and efficient production of a self-restricted, self-tolerant T-cell repertoire. Despite their functional differences, cTEC and mTEC initially arise from a common progenitor TEC, and the forkhead transcription factor FOXN1, expressed exclusively in thymic and cutaneous epithelia, is required at multiple stages for differentiation of both sublineages2,3,8,9. Neonatal thymus transplantation can confer adaptive immunity to congenitally athymic patients31 but its widespread use is limited by donor tissue supply and histocompatibility; these limitations would be overcome if functional TECs could be generated or expanded in vitro. Several investigators have reported derivation of TEC-like cells from pluripotent cells by directed differentiation using growth factors12–16, however, neither generation from these TEC-like cells of an organized thymus containing all TEC subtypes, nor their capacity to support T-cell development in vitro has been demonstrated. Although in one report TECs expressing the transcription factor autoimmune regulator (AIRE), which are critical for the establishment of self-tolerance17, were detected after transplantation of the pluripotent cell-derived TECs, there, no demarcation of cortical and medullary compartments was evident18. In sum, the challenge of generating therapeutically useful TECs in vitro that can form a fully functional thymus on transplantation remains unsolved. Here, we have examined two questions: first, whether the alternative approach of direct reprogramming can be used to generate functional TECs in vitro, and second, whether artificial TECs derived by this method can generate a complete thymus on transplantation.

To address the first question, we tested the outcome of enforcing expression of FOXN1, our candidate reprogramming factor, in primary mouse embryonic fibroblasts (MEFs). For this purpose, we developed a transgenic mouse line in which a full-length Foxn1 complementary DNA under the control of the CAG promoter was knocked into the Rosa26 locus, with a LoxP-flanked transcriptional STOP cassette inserted between the CAG promoter and the Foxn1 cDNA (Rosa26\textsuperscript{CAG–STOP–Foxn1–IRES–GFP}).
Figure 1 Enforced FOXN1 expression induces epithelial identity in fibroblasts. (a) iFoxn1 transgene. (b) Schematic showing the procedure for generating iFoxn1 MEFs. (c) GFP expression in iFoxn1 and Rosa26<sup>CreERT2</sup> (control) MEFs 10 days after 4-hydroxy tamoxifen (4OHT) treatment. (d) Foxn1 mRNA expression in iFoxn1 and Rosa26<sup>CreERT2</sup> control MEFs 10 days after 4OHT treatment, and E15.5 wild-type EpCAM<sup>+</sup> fetal TEC, normalized to the geometric mean of two housekeeping genes. Data shown are mean ± s.d. from n = 3 independent experiments. (e) Bright-field (left) and immunofluorescence images (right) showing morphology and K8 staining, 10 days after 4OHT treatment. Scale bars, 100 μm. (f) EpCAM and GFP expression 10 days after 4OHT treatment, after gating on live cells. Values shown are mean ± s.d. from n = 3 independent experiments. (g-i) mRNA expression levels of the genes shown in purified EpCAM<sup>+</sup> iFoxn1 and control MEFs normalized to the geometric mean of two housekeeping genes. Data shown are mean ± s.d. from n = 3 independent experiments (NS, not significant; *P < 0.05). In g, expression level is shown relative to E15.5 EpCAM<sup>+</sup> fetal TEC or skin. In d,g,i, blue bars, Rosa26<sup>CreERT2</sup>CAG–Foxn1–IRES–GFP (iFoxn1); grey bars, fetal TEC, except right hand panel in g, where black bars represent skin. For c-i n ≥ 3 independent experiments. Three technical replicates were run for each n. cDNA was generated from 200 cells using a one-step RT-qPCR method with amplification (d,g,h) or from 50,000 cells without amplification (i). Error bars or values show mean ± s.d. Ctrl, control. See also Supplementary Figs 1 and 2.

Fig. 1a and Supplementary Fig. 1). Crossing with Rosa26<sup>CreERT2</sup> mice generated Rosa26<sup>CreERT2</sup>CAG–Foxn1–IRES–GFP embryos, from which we derived primary MEFs. Tamoxifen-induced Cre-mediated excision of the STOP cassette in these MEFs generated Rosa26<sup>CreERT2</sup>CAG–Foxn1–IRES–GFP (iFoxn1) MEFs, in which Foxn1 expression was induced at levels comparable to fetal TECs (Fig. 1b–d); tamoxifen-independent Cre-mediated excision was not detected (Supplementary Fig. 2).

By ten days after initiation of Foxn1 expression, the morphology of iFoxn1 MEFs had changed from an elongated, bipolar shape characteristic of fibroblasts, to a broader, polygonal shape, characteristic of epithelial cells (Fig. 1e). The identity of these cells was probed using the epithelial-specific markers keratin 8 (K8) and epithelial cell adhesion molecule (EpCAM), which are expressed by all TECs during early thymus development<sup>9,19</sup>. Most, if not all, iFoxn1 MEFs, but no control MEFs, expressed K8 (Fig. 1e), and approximately 15% expressed EpCAM (Fig. 1f), suggesting that FOXN1 induction had converted the fibroblasts to an epithelial-like state.

To investigate the identity of the epithelial-like iFoxn1 MEFs, we isolated EpCAM<sup>+</sup> cells and analysed them for expression of TEC- (Dll4, Ccl25 and Kitl; refs 9,19) and cutaneous epithelium- (Fgf2 and Krt1; ref. 20) specific FOXN1-regulated genes. The iFoxn1 MEFs but not control MEFs expressed Dll4, Ccl25 and Kitl at levels comparable to fetal TECs, but did not express cutaneous epithelium-associated genes (Fig. 1g). Other TEC-associated genes not previously implicated as FOXN1 targets, Epithelial V-like antigen (Eva or Mpz12), which
is broadly expressed in TECs, and Pax9 and Tpr63 (ref. 19), which are differentially expressed among TEC subsets, were also induced in iFoxn1 MEFs (Fig. 1h). We consistently detected low levels of endogenous Foxn1 (Fig. 1i), indicating a direct auto-regulatory mechanism and/or indirect activation of endogenous Foxn1 as part of an initiated TEC differentiation programme. Collectively, enforced FOXN1 expression in MEFs induces genes involved in TEC development and function, suggesting a FOXN1-mediated conversion of MEFs into TEC-like cells (designated iTECs hereafter). FOXN1 is also expressed in cutaneous epithelium, yet here clearly induces a transcriptional programme characteristic of TECs rather than cutaneous epithelium. Although the reasons for this are not understood, the gene expression programme in TECs clearly shares some elements with that of cutaneous epithelium (p63, keratins, some claudins). This may relate to the high levels of FOXN1 induced in our system, and to the intracellular context provided by the iTEC-induction protocol.

To test the functional attributes of the iTECs, we determined their capacity to support T-cell development in vitro. A monolayer of iTECs, in which FOXN1 had been induced for seven days, was seeded with fetal Lin−/CD25−/C-Kit+ early T lineage progenitors (ETPs). Analysis after 12 days of co-culture (Fig. 2a) revealed the presence of CD4+CD8α+ double-positive (CD4+CD8α+ DP), CD4α− single-positive (CD4α− SP) and CD8α+ single-positive (CD8α+ SP) cells, with the subset distribution on the iTEC monolayers closely resembling that of the adult mouse thymus (Fig. 2b). As expected, the T cells generated on the iTEC monolayer expressed both CD3ε and T-cell antigen receptor beta (TCRβ; Fig. 2c,d). In contrast, EPSCs seeded onto control MEFs did not enter thymopoiesis (Fig. 2b); instead, most haematopoietic cells remaining after co-culture on MEFs expressed the B-cell marker B220 (Fig. 2c). Consistent with the requirement for MHC Class II on TECs for positive selection and therefore efficient generation of CD4+SP thymocytes, EpCAM+ iTECs showed robust expression of MHC Class II after co-culture with thymocytes (Fig. 2e). Surface MHC Class II was not evident in iTECs before co-culture, demonstrating that the cells generated by the initial reprogramming step differentiated on exposure to developing T cells, as observed for TECs within the native thymus in vivo. Interestingly, the capacity of iTECs to support thymocyte development was dependent on their plating density, with a high density (>500 cells mm−2) producing >3 times more CD4+CD8α+ T cells within 12 days than a lower density (<250 cells mm−2; Supplementary Fig. 3). However, the addition of fibroblast growth factor 7 (FGF7; ref. 23) to low-density iTECs substantially improved their ability to support T-cell development (Supplementary Fig. 3), consistent with the established role of FGF7 as a mitogen for fetal and postnatal TECs (ref. 23). Of note, FGF7 does not affect fibroblast proliferation, and Fgfr2Iib, the receptor for FGF7 and FGF10, is required for normal thymus development. The kinetics of T-cell development were similar when ETPs were seeded onto iTECs or the stromal cell line OP9-DL1 (Supplementary Fig. 4), although as expected, development of CD4+ SP thymocytes was typically more efficient in iTEC cultures (Supplementary Fig. 4). Collectively, iTECs can robustly support T-cell development in vitro, with thymocyte differentiation to the CD4+ and CD8α+ stages closely mirroring in vivo differentiation. Although further work is required to test the capacity of iTECs to support T-cell development from the circulating lympho-myeloid proliferating progenitor, which is considered to...
Figure 3  iTECs form a functional thymus in vivo. (a) Schematic of grafting assay. iTECs (5 days following FOXN1 induction) or control MEFs were aggregated with E12.5–13.5 wild-type CD45−Lin− thymocytes and E12.5–13.5 wild-type CD45−PDGFRα− thymic mesenchymal cells, and grafted under the kidney capsule of adult mice. Lin: CD3ε, CD4, CD8, CD11b, CD11c, B220, Gr-1, NK1.1, Ter119. (b) Summary of recovered grafts.

(c) Haematoxylin and eosin staining (left), and pan-cytokeratin (panK; right) staining of an iTEC-derived kidney graft. m, medulla; c, cortex; scale bar, 500 μm. (d,e) Analysis of iTEC grafts, and wild-type (WT) thymi from 8-week-old mice. (e) CD45−EpCAM+ cells from the gate defined in (d); GFP expression reports CAG–iFoxn1. Data shown are representative and are from 1 of at least 3 independent experiments.

be the thymus-seeding haematopoietic progenitor that gives rise to mature T cells\(^ {25,26}\), we anticipate that iTECs will have this capacity as it is well established that lympho-myeloid proliferating progenitors differentiate into T cells in co-culture with OP9-DL1 cells\(^ {25,27,28}\).

To address our second question, of whether the iTECs, an artificial cell type generated in vitro, could form an organized and functional thymus, we aggregated iTECs (5 days after induction of FOXN1) or control MEFs with immature thymocytes (CD45−Lin−) and fetal thymic mesenchyme from embryos at day 12.5 to 13.5 of development (E12.5–13.5) (CD45−PDGFRα+), and grafted the resulting cell aggregate under the kidney capsule of syngeneic adult mice\(^ {29,30}\) (Fig. 3a). Fetal thymic mesenchyme was included to ensure that growth factors essential for expansion of the thymus, including FGF10 and IGF (refs 23,31,32), were available within the graft. Macroscopic, well-formed organs were recovered 4 weeks post-grafting from recipients of iTEC, but not control MEF-only, grafts (Fig. 3b). These iTEC-derived organs exhibited a characteristic thymus morphology, with multiple clearly defined cortical and medullary regions evident in all grafts (Fig. 3c). Pan-cytokeratin staining revealed a reticular network of epithelial cells throughout the organs (Fig. 3c), while flow cytometric analysis indicated that haematopoietic and epithelial cells were present in similar proportions in the recovered iTEC grafts to in the native adult thymus (Fig. 3d). All EpCAM+ cells in the iTEC grafts expressed GFP, reporting the transgenic iFoxn1-IRES-GFP messenger RNA, confirming they were derived from the input iTECs (Fig. 3e).

Thymus architecture and function are intimately linked, and furthermore, the presence of discrete TEC subsets within the cortical and medullary compartments is required for full functionality of the organ\(^ {33}\), including for inducing central tolerance in the emerging T-cell repertoire\(^ {33}\). Correctly compartmentalized regions of cTECs
Figure 4 Intrathymic T-cell development in iTEC-derived grafts. (a, b) Immunohistochemical analyses of iTEC grafts and wild-type (WT) thymi using cTEC (CD205 and β5t) and mTEC (keratin 14 (K14) and UEA-1)-specific markers, and anti-AIRE. Scale bars: 150 μm (a), 25 μm (b). (c) Flow cytometry of MHC Class II expression for the CD45-EpCAM+ cells defined in Fig. 3d. Gates show MHC Class IIhi and MHC Class IIlo populations defined using wild-type TECs. In a–c, the data shown are representative and are from 1 of at least 4 independent experiments. (d) RT-qPCR analysis of 50 CD45+ EpCAM+ MHC Class IIhi iTECs, recovered from a single graft 7 weeks post-transplantation, for the markers shown. Data are shown relative to expression in E15.5 wild-type total EpCAM+ TECs after normalization to two housekeeping genes (Hmbs and Tbp); expression level in E15.5 wild-type is 1 for all samples. Values shown are from 1 experiment. (e–h) Analysis of 8-week-old wild-type mouse thymus, iTEC grafts or cells collected from a control MEF graft site at 4 weeks post-transplantation. (e) CD4 and CD8 expression after gating on CD45+ cells. (f) Percentage of CD4+CD8+ T cells. (g) TCRβ expression. (h) TCRγδ expression on CD4–CD8– thymocytes. In e–g, data shown are representative and are from 1 of at least 4 independent experiments, in f each data point represents a separate graft from n = 4 independent experiments, and in h data shown are from 1 experiment.

and mTECs were evident in the iTEC-derived grafts, and expressed region-appropriate markers (CD205 and keratin 14 respectively18,34; Fig. 4a). The functional cTEC marker β5t (ref. 35), and the UEA-1hi subpopulation of mTECs (ref. 9), were also evident (Fig. 4a). Functional competence was further demonstrated by the presence of AIRE+ mTEC (ref. 33) and MHC Class IIhi and MHC Class IIlo TEC populations (Fig. 4b,c). iTECs recovered from the grafts expressed a range of markers associated with TEC differentiation and function at or close to the levels normally present in TECs (Fig. 4d). Thus, iTECs were able to differentiate to generate a functional thymus containing all of the major TEC populations and exhibiting the architectural characteristics diagnostic of a fully functional native thymus.

A crucial question was whether the iTEC-derived grafts supported normal T-cell development, and hence population of the peripheral immune system with newly generated naive T cells. Thymocyte subset distribution in the iTEC-derived grafts closely matched that of the native adult thymus (Fig. 4e,f). Distribution of TCRβ expression within iTEC grafts was near identical to that observed within the native thymus, with TCRβhi cells restricted to CD4+ SP and CD8+ SP populations (Fig. 4g). TCRγδ+ T cells were present within CD4–CD8– double-negative (DN) populations, again at a comparable proportion in the iTEC grafts and native thymus (Fig. 4h). No macroscopic grafts were recovered from MEF-graft recipients, and no evidence of thymopoiesis could be found in tissue adjacent to the graft site in any MEF-graft recipient mice (Fig. 4e,f). The T cells generated in the iTEC grafts were exported to populate the peripheral immune system. Peripheral blood analysis revealed the presence of CD4+ and CD8+ T cells, and Foxp3+ regulatory T cells in two of three nu/nu iTEC recipient mice by 8 weeks post grafting, with numbers continuing to rise over time, whereas no donor-derived peripheral
iTECs thus represent a clear and essential step towards the generation of patient-specific T cells in culture. They further demonstrate that iTECs generate a properly patterned, functional organ on transplantation in vivo, composed of cTECs and mTECs that express markers diagnostic of each cell type, including markers critical for T-cell lineage differentiation and repertoire selection. To our knowledge this is the first demonstration of the generation of a complete, organized and functional, complex organ from reprogrammed cells. Our data thus identify iTECs as a new and readily available source of TECs, that may provide the basis for thymus transplantation therapies aimed at boosting adaptive immune system function in immunocompromised patients.

**METHODS**

Methods and any associated references are available in the online version of the paper.

*Note: Supplementary Information is available in the online version of the paper.*
ACKNOWLEDGEMENTS

We thank O. Rodrigues and C. Cryer for cell sorting, V. Berno for imaging, F. H. Stenhouse and C. D. Peddie for technical assistance and J. Mee for kidney grafting; R. Zamosyska, R. Brownie and G. Cowan for advice, W. Wilson, K. Kaji, A. G. Smith, I. Chambers and N. Hastie for comments on the manuscript, and the Biological Research Facility staff for animal care. The research leading to these results received funding from Leukaemia and Lymphoma Research (C.C.B. and N.B.), the Darwin Trust of Edinburgh (S.U.), the School of Biological Sciences, University of Edinburgh (H.J.V.), the Medical Research Council (C.C.B.), the European Union Seventh Framework Programme (FP7/2007–2013) collaborative projects EuroSyStem (C.C.B. and N.B.) and ThymiStem (C.C.B., S.U., K.E.O’N) under grant agreement numbers 200720 and 602587, respectively, and NIH/NIAMD grant no. R01 AI082127 (N.R.M.).

AUTHOR CONTRIBUTIONS

N.B. generated the ifoxn1 allele, conceived and designed experiments, performed experiments, analysed the data and contributed to writing the manuscript; N.R.M. contributed to experimental design and to writing the manuscript; S.U., K.E.O’N and H.J.V. performed experiments and contributed to analysis of the data; C.C.B. conceived the original idea, designed experiments, contributed to analysis of the data and wrote the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at www.nature.com/doifinder/10.1038/ncb3023

Reprints and permissions information is available online at www.nature.com/reprints

1. Graf, T. & Enver, T. Forcing cells to change lineages. Nature 462, 587–594 (2009).
2. Nehls, M. et al. Two genetically separable steps in the differentiation of thymic epithelium. Science 272, 886–889 (1996).
3. Blackburn, C. C. et al. The riu gene acts cell-autonomously and is required for differentiation of thymic epithelial progenitors. Proc. Natl Acad. Sci. USA 93, 5742–5746 (1996).
4. Ritter, M. A. & Boyd, R. L. Development in the thymus: It takes two to tango. Immunol. Today 14, 462–469 (1993).
5. Miller, J. F. A. P. Immunological function of the thymus. Lancet 2, 748–749 (1961).
6. Chinn, I. K., Blackburn, C. C., Manley, N. R. & Sempowski, G. D. Changes in primary lymphoid organs with aging. Semin. Immunol. 24, 309–320 (2012).
7. Lynch, H. E. et al. Thymic involution and immune reconstitution. Trends Immunol. 30, 366–373 (2009).
8. Manley, N. R., Richie, E. R., Blackburn, C. C., Condie, B. G. & Sage, J. Structure and function of the thymic microenvironment. Front. Biosci. 16, 2461–2477 (2011).
9. Nowell, C. S. et al. Foxn1 regulates lineage progression in cortical and medullary thymic epithelial cells but is dispensable for medullary sublineage divergence. PLoS Genet. 7, e1002348 (2011).
10. Bleul, C. C. et al. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 441, 992–996 (2006).
11. Markert, M. L. et al. Transplantation of thymus tissue in complete DiGeorge Syndrome. N. Engl. J. Med. 341, 1180–1189 (1999).
12. Lai, L. & Jin, J. Generation of thymic epithelial cell progenitors by mouse embryonic stem cells. Stem Cells 27, 3012–3020 (2009).
13. Lai, L. et al. Mouse embryonic stem-cell-derived thymic epithelial cell progenitors enhance T-cell reconstitution after agenetic bone marrow transplantation. Blood 118, 3410–3418 (2011).
14. Inami, Y. et al. Differentiation of induced pluripotent stem cells to thymic epithelial cells by phenotype. Immunol. Cell Biol. 89, 314–321 (2011).
15. Panzer, A. V. et al. Generation of functional thymic epithelium from human embryonic stem cells that supports host T cell development. Cell Stem Cell 13, 219–229 (2013).
16. Sun, X. et al. Directed differentiation of human embryonic stem cells into thymic epithelial progenitor-like cells reconstitutes the thymic microenvironment in vivo. Cell Stem Cell 13, 230–236 (2013).
17. Mathis, D. & Benoist, C. Aire. Annu. Rev. Immunol. 27, 287–312 (2009).
18. Klug, D. B. et al. Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. Proc. Natl Acad. Sci. USA 95, 11822–11827 (1998).
19. Manley, N. R. & Condie, B. G. Transcriptional regulation of thymus organogenesis and thymic epithelial cell differentiation. Prog. Mol. Biol. Transl. Sci. 92, 103–120 (2010).
20. Weiner, L. et al. Dedicated epithelial recipient cells determine pigmentation patterns. Cell 130, 932–942 (2007).
21. Allman, B. et al. Thymopoiesis independent of common lymphoid progenitors. Nat. Immunol. 4, 168–174 (2003).
22. Klug, D. B., Carter, C., Gimenez-Conti, I. B. & Richie, E. R. Cutting edge: thymocyte-independent and thymocyte-dependent phases of epithelial patterning in the fetal thymus. J. Immunol. 169, 2842–2845 (2002).
23. Revest, J. M., Suniara, R. K., Kerr, K., Owen, J. J. & Dickson, C. Development of the thymus requires signaling through the fibroblast growth factor receptor R2-IIib. J. Immunol. 167, 1954–1961 (2001).
24. Rubín, J. S. et al. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc. Natl Acad. Sci. USA 86, 802–806 (1989).
25. Adolfsson, J. et al. Identification of Fli3+ lympho-myeloid stem cells lacking erythromegakaryocytic potential. A revised road map for adult blood lineage commitment. Cell 121, 295–306 (2005).
26. Lu, C. et al. The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential. Nat. Immunol. 13, 412–419 (2012).
27. Schmitt, T. M. et al. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat. Immunol. 5, 410–417 (2004).
28. La Motte-Mohs, R. N., Herer, E. & Zuniga-Pflucker, J. C. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like-1 in vitro. Blood 105, 1431–1439 (2005).
29. Bennett, A. R. et al. Identification and characterization of thymic epithelial progenitor cells. Immunity 16, 803–814 (2002).
30. Sheridan, J. M., Taoudi, S., Medwinsky, A. & Blackburn, C. C. A novel method for the generation of reaggregated organotypic cultures that permits juxtaposition of defined cell populations. Genesis 47, 346–351 (2009).
31. Auerbach, R. Morphogenetic interactions in the development of the mouse thymus gland. Dev. Biol. 2, 271–284 (1960).
32. Jenkinson, W. E., Rossi, S. W., Parnell, S. M., Jenkinson, E. J. & Anderson, G. PDGFRα-expressing mesenchyme regulates thymus growth and the availability of intrathymic niches. Blood 109, 954–960 (2007).
33. Abramson, J., Giraud, M., Benoist, C. & Mathis, D. Aire’s partners in the molecular control of immunological tolerance. Cell 140, 123–135 (2010).
34. Shakib, M. et al. Checkpoints in the development of thymic cortical epithelial cells. J. Immunol. 182, 130–137 (2009).
35. Murata, S. et al. Regulation of CDB+ T cell development by thymus-specific prosecretases. Science 316, 1349–1353 (2007).
36. Schmitt, T. M. & Zuniga-Pflucker, J. C. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 17, 749–756 (2002).
37. Dervovic, D. D. et al. Cellular and molecular requirements for the selection of in vitro-generated CD8 T cells reveal a role for Notch. J. Immunol. 191, 1704–1715 (2013).
38. Hameyer, D. et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol. Genomics 31, 32–41 (2007).
39. Wallace, H. A. et al. Manipulating the mouse genome to engineer precise functional systemic replacements with human sequence. Cell 128, 197–209 (2007).
40. Gray, D. H. et al. Unbiased analysis, enrichment and purification of thymic stromal cells. J. Immunol. Methods 329, 56–66 (2008).
METHODOLOGY

Ethics statement. All animal work was conducted according to UK Home Office guidelines, as established in the Animals (Scientific Procedures) Act 1986.

Mice. Rosa26(CAG-STOP-foxn1-MES-GFP+) mice were backcrossed onto the C57BL/6 background for at least 5 generations then maintained by intercrossing. Rosa26C5B12 (ref. 38) mice were maintained as homozygotes. Six-week- to 6-month-old male Rosa26C5B12 mice were crossed with 6–12-week-old Rosa26(CAG-STOP-foxn1-MES-GFP+)/ female mice as described to generate Rosa26C5B12(CAG-foxn1-MES-GFP) (foxn1) mice. One pregnant iFoxn1 mouse was euthanized to generate each batch of mouse embryonic fibroblasts (MEFs)/iTects. For timed matings, noon of the day of the vaginal plug was taken as day 0.5.

Generation of the iFoxn1 targeting vector. A construct containing the targeting cassette (Fig. 1a and Supplementary Fig. 1a) was generated by standard molecular biology techniques and verified by sequencing. Conventional subcloning was used for all cloning steps.

Southern blotting. Genomic DNA was processed for Southern blotting as described previously5.

Gene targeting and blastocyst injection. Mouse Sv129/Ola embryonic stem cells (line E14tg2a) were electroporated with linearized targeting vector (Supplementary Fig. 1b) and grown under geneticin selection. Correctly targeted clones were identified by Southern analysis (Supplementary Fig. 1b), expanded and injected into C57BL/6 blastocysts to generate chimaeric mice. Germ-line transmission was confirmed for two independently targeted cell clones (Supplementary Fig. 1b); the resulting mouse line was designated Rosa26(CAG-STOP-foxn1-MES-GFP+)/(called iFoxn1 herein). The neomycin resistance cassette was removed by crossing of founder iFoxn1 mice with Tg(CAG-FLPe) mice7. The E14tg2a embryonic stem cell line used to generate the R26-CAG-STOP-Foxn1-IRES-GFP mouse strain was routinely tested for normal karyotype and is tested free of mycoplasma contamination.

MEF isolation. MEFs were prepared from E13.5 embryos decapitated and stripped of all internal organs and trypsinized into a single-cell suspension. Cells were plated in DMEM containing 10% fetal calf serum, 2 mM sodium pyruvate, 4 mM glutamine, 50 µg ml−1 streptomycin and 50 µM penicillin (DMEM/FCS). Each MEF line was genotyped using the following primers to detect the iFoxn1 allele: iFoxn1F 5′-GGGAGCAGCTGAAGGATGAC-3′ and iFoxn1R 5′-CGCTTGAGGAGAGCCATTTG-3′. Rosa26C5B12(CAG-foxn1-MES-GFP) (Foxn1) and Rosa26C5B12/(Control) MEFs were used for all experiments. MEFs were freshly purified after gating against CD45−/CD11b, CD11c, B220, Gr-1, NK1.1, Ter119). Mesenchymal cells (PDGFRα+ or DN1 (CD45+/CD122−/CD44−/CD25−/IL-7Rα−) were isolated from the lymph nodes of mice. Data were acquired using a LSR Fortessa (BD Biosciences) and analysed using FlowJo software (Tree Star).

For sorting, fetal thymi were enzymatically digested to single-cell suspensions as described previously22. Total (CD45+Lin−) or DN1 (CD45+Lin−CD25−/IL-7Rα−) thymocytes were purified after gating against Lin+ cells (Lin: CD3e, CD4, CD8, CD11b, CD11c, B220, Gr-1, NK1.1, Ter119). Mesenchymal cells (PDGFRα+) were purified after gating against CD45+ Ter119− cells. Cell sorting was performed using a FACSAria (BD Biosciences).

Immunohistochemistry. Adult thymi and recovered graft thymi were processed for immunohistochemistry as described previously23. Isotype controls were included in all experiments. Staining was analysed using a Leica AOB5 confocal microscope (Leica Microsystems GmbH). The images presented are either single optical sections or projected focus stacks of serial optical sections.

RNA isolation. RNA was prepared using the RNaseasy mini kit (Qiagen) according to the manufacturer’s instructions. All samples were DNase treated.

Quantitative PCR with reverse transcription (RT-qPCR). cDNA was prepared using the Superscript III first strand synthesis kit (Invitrogen) with Oligo-dT primers, according to the manufacturer’s instructions. Relative expression levels were determined using the Roche Universal Probe Library on the Roche Lightcycler 480 after normalization to the geometric mean of two housekeeping genes (Hmbs and Tbp) for all experiments. Technical triplicates were run for all samples and no RT and no template controls were included in all experiments. The primers used for RT-qPCR are listed in Supplementary Table 2. For the analysis presented in Fig. 4d, 50 cells were sorted into CellsDirect 2x Reaction Mix (Invitrogen) supplemented with RNase inhibitor (Ambion). cDNA was synthesized and pre- amplified in a single step using CellsDirect Superscript III reverse transcriptase/Platinum Taq mix (Invitrogen) and gene-specific primers. Thermal cycling conditions were as follows: 50 °C for 15 min; 95 °C for 2 min; 18 cycles of 95 °C for 15 s, 60 °C for 4 min.

Statistical analysis. Statistical analysis was performed using the one-way analysis of variance test (two-tailed), as appropriate for normally distributed data (normal distribution was tested using χ2 goodness of fit). The α level is taken as 0.05. Errors shown are standard deviations (s.d.) throughout. Sample sizes of at least n = 3 were used for statistical analyses except where indicated. No statistical method was used to predetermine sample size, the experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment. There were no limitations on repeatability of the experiments and no samples were excluded from the analysis.
Supplementary Figure 1 related to Figure 1. Generation of transgenic Rosa26CAG-STOP-Foxn1-IRES-GFP mice. 

a, The CAG-STOP-Foxn1 cassette shown in Figure 1 was introduced into the Rosa26 locus in mouse E14tg2a ES cells by homologous recombination using standard procedures, generating the Rosa26CAG-NeoR-STOP-Foxn1-IRES-GFP allele. This cassette contained a cDNA encoding Foxn1 under control of the CAG compound promoter and downstream of a LoxP-flanked CMAZ stop cassette plus an IRES-GFP component to permit monitoring of Foxn1 expression. Neomycin-resistant colonies were picked and screened for targeted insertion by Southern blotting, using the strategy shown in (a) above. The position of restriction enzyme sites and Southern blot hybridization probes are shown for the wild type and transgenic Rosa26 locus. EcoRI, EcoRV and PacI restriction enzyme digests were used for 5’, 3’ and internal Southern blot analyses, respectively. 

b, Correctly targeted colonies were identified and used to generate chimeric mice via blastocyst injection. Germline transmission was confirmed from two independent ES cell lines (L1 and L2). Founders from each of these Rosa26CAG-NeoR-STOP-Foxn1-IRES-GFP lines were crossed with Tg(CAG-FLPe) mice in order to remove the neomycin resistance cassette (NeoR). These lines were then backcrossed to C57BL/6 mice for five generations before analysis.
**Supplementary Figure 2** related to Figure 1. Absence of tamoxifen-independent Cre-recombinase activity in \textit{Rosa26CAG-STOP-Foxn1-IRES-GFP} MEFs. MEFs of the genotypes shown were isolated and treated with 1\(\mu\)M 4OHT or carrier solution for 48 hours, then (A) analyzed by flow cytometry for expression of GFP and EpCam after a further 4 days in culture, or (B) analyzed for Foxn1 mRNA expression by RT-qPCR (without further culture). Data in (B) show Foxn1 mRNA expression relative to the geometric mean of 2 housekeepers, determined for two Foxn1 primer/UPL probe sets, Foxn1 68 and Foxn1 32. No GFP or Foxn1 expression was detected in the absence of tamoxifen/4OHT, indicating that leakiness caused by ligand-independent Cre-recombinase activity did not occur in this system.
Supplementary Figure 3 related to Figure 2. iFoxn1TEC are responsive to Fgf7 in vitro. Plots show flow cytometric analysis of CD45+ cells following co-culture on iTEC for 12 days in the presence or absence of Fgf7. iTEC (five days after induction of Foxn1) were plated at low density (5×10⁴ cells per well) or high density (2×10⁵ cells per well) into a 24-well plate. Following a further 2 days each well was seeded with 3×10⁵ ETP thymocytes (CD45+Lin⁻CD25⁻C-Kit⁻) isolated from E14.5 fetal thymi and cultured for 12 days before analysis.
Supplementary Figure 4 related to Fig. 2. Comparison of the kinetics of T cell development in vitro from ETP seeded onto iTEC or OP9-DL1 cells. ETP were isolated from E14.5 fetal thymi and seeded at a density of 3000 cells per well onto OP9-DL1 cells (plated the previous day at a density of 2x10^4 per well) or iTEC (density 2x10^5) in 24 well plates. The OP9-DL1/ETP co-cultures were subsequently cultured in medium containing IL7 (5ng/ml) and Flt3L (5ng/ml) (Porrit et al., 2004) until day 6 of culture, then IL7 (1ng/ml) and Flt3L (5ng/ml) until the end of the experiment, while the iTEC/ETP and control MEF/ETP co-cultures were cultured in medium containing IL7 (1ng/ml) and Flt3L (5ng/ml) throughout. Cultures were analyzed by flow cytometry with the markers shown after 4, 8 or 12 days of co-culture. n=1.

Note that the iTEC used for the above experiments were made by isolating MEFs from E13.5 Rosa26^CAG-STOP-Foxn1-IRES-GFP embryos; these MEFs were expanded in culture for 4 days, then treated with 1μM 4OHT for 48 hours. The following day, GFP^+ cells were isolated by flow cytometric cell sorting, then plated into 24 well plates at a density of 2x10^5 cells per well. They were seeded with ETPs 3 days later. This protocol differs slightly from the protocol used in Figure 2.
Supplementary Figure 5 related to Fig. 5. Haplotype analysis demonstrates the presence of donor-derived T cells in iTEC-graft recipients. Representative analysis of splenocytes from iTEC-grafted or control-grafted nu/nu mice seven weeks post-transplantation, and wild type (WT) C57BL/6xCBA F1 mice. Plots show staining for H2Kk on CD4+ and CD8+ splenocytes after gating on live cells. The donor ETP within the iTEC and control grafts were from C57BL/6xCBA F1 embryos and therefore expressed b and k haplotypes of MHC Class I and II antigens. The recipient mice were CD1 nu/nu, which are of undetermined haplotype, but do not express H2Kk as shown. Most splenic T cells in the iTEC recipients are donor-derived (i.e. express H2Kk).
### Supplementary Table 1. Antibodies used for immunofluorescence and flow cytometry. FC, flow cytometry; IF, immunofluorescence

| Antibody | Clone | Supplier | Dilution | Staining |
|----------|-------|----------|----------|----------|
| Aire (M-300) | Polyclonal | SCBT | 1/300 | IF
| beta 2 Microglobulin | Polyclonal | MBL International | 1/200 | FC – Lineage (DN sort), T cell analysis
| CD11b | FITC | E-Genomics | 1/200 | FC – Lineage (DN sort)
| CD205 | PE | BioLegend | 1/100 | FC – Lineage (DN sort)
| CD25 | PE | BioLegend | 1/100 | FC – Lineage (DN sort)
| CD3e | FITC | E-Genomics | 1/200 | FC – T cell analysis
| CD4 | FITC | BD Biosciences | 1/200 | FC – Lineage (DN sort), T cell analysis
| CD45R0 | PE | BD Biosciences | 1/200 | FC – Lineage (DN sort)
| CD8a | PE | BioLegend | 1/200 | FC – T cell analysis
| C-Kit | APC | BioLegend | 1/100 | FC – Lineage (DN sort)
| Cytokeratin 14 (AF64) | Polyclonal | Covance | 1/800 | IF
| DAPI | (4',6-Diamidino-2-phenylindole, Dihydrochloride) | Life Technologies | 0.5ug/ml (FC); 5ug/ml (IF) | Viability dye
| EpCAM | APC | BioLegend | 1/400 | FC – MEIP/graft analysis
| Foxp3 | A288-50 | BioLegend | Manufacturer’s instructions | FC – T cell analysis
| Gr-1 | FITC | eBioscience | 1/200 | FC – Lineage (DN sort)
| H-2 | - | - | - | FC
| MHC Class II | PE-Cy7 | BioLegend | 1/800 | FC – MEIP/graft analysis
| NK1.1 | FITC | BioLegend | 1/800 | FC – MEIP/graft analysis
| Pan-Cytokeratin | Polyclonal | Dako | 1/800 | FC – Lineage (DN sort)
| PDGFRa | APC | BioLegend | 1/200 | FC – Mesenchyme sort
| PDGFRb | APC | BioLegend | 1/200 | FC – Mesenchyme sort
| TCRb | PerCP-Cy5.5 | BioLegend | 1/200 | FC – T cell analysis
| Ter119 | FITC | BioLegend | 1/200 | FC – T cell analysis
| UEA-1 | biotin | Vector Labs | 1/400 | FC – Lineage (DN sort)

© 2014 Macmillan Publishers Limited. All rights reserved.
### Supplementary Table 2. Primers used for RT-PCR

| Gene     | Forward primer (5'-3') | Reverse primer (5'-3') |
|----------|------------------------|------------------------|
| CCL25    | GAGTGCCACCCTAGGTGACG   | CCAGCTGCTGCTCTGAGCTA   |
| CD205    | CTCACGTGGCTATGCAAGAGG  | GGATGGCTATGCCTGCTAGTT  |
| CTSL     | CAAATAAGAATATATGCTTGTAA| TCGTCTTCAACAGTGCTCCAG  |
| CXCL12   | GGTTCCTGCAGAGGCCACA    | TGTTCTTACAGGCTGCAA     |
| DII4     | AGGTGCCACTTCTGTACACAG  | GGGAGAGCAATGGCTGATA    |
| EVA      | TGTGCTTCCACTTCTCTCTGA  | TCCACAGCTTCTGAGGACAAA  |
| Fgf2     | CGGCTCTACTGCAAGACCG    | TGCTTTGAGTTGATTTAGGCA  |
| FgfR2IIIB| CGGGGTTGTTGAGGTCTTCA   | CCTGCGGAGACAGGTAACAA   |
| Foxn1 32 | CTCTCAGTGACTTCGACTTCA  | CGACGAGGCTCACAATACG    |
| Foxn1 68 | TGACGGAGCATTCCCTTACAG  | GACAGGGTTAGGCGAACAGAA  |
| Foxn1-3'UTR| CTTAAAGGCTAAGGAAGGAACACT| GGCTAAACAAATAAGTTGCGTGA|
| HMBS     | TCCCTGAGGATGTGCCTAC    | ACAAGGTGGTTCCGGTCCTTG  |
| Keratin 1| CCAGGTGCTACAAACCAATG   | GTTTGGTTCCGGGTGTG       |
| Kit L    | TCAACATTAGGTCCAGAGAAA  | ACTGCTACTGCTGCTATTGTAAG|
| P63      | GGAAACAAATGCCGAGACTC   | AATCTGCTGCTCCATGCTGT   |
| Pax9     | AGCGAGAAGCAAGTACG      | TGGATGCTGACGAAACTCG    |
| TBP      | GGGGAGCTGATGCGTGAAGT   | CCAGGAAATAATTCGGCTCA   |